nodes	percent_of_prediction	percent_of_DWPC	metapath
Apraclonidine—Clonidine—CYP1A1—breast cancer	0.00143	0.343	CrCbGaD
Apraclonidine—Clonidine—CYP2D6—breast cancer	0.00106	0.255	CrCbGaD
Apraclonidine—Clonidine—CYP3A4—breast cancer	0.000911	0.219	CrCbGaD
Apraclonidine—Clonidine—ABCB1—breast cancer	0.000759	0.182	CrCbGaD
Apraclonidine—Headache—Thiotepa—breast cancer	0.00037	0.000452	CcSEcCtD
Apraclonidine—Somnolence—Paclitaxel—breast cancer	0.00037	0.000452	CcSEcCtD
Apraclonidine—Palpitations—Capecitabine—breast cancer	0.00037	0.000452	CcSEcCtD
Apraclonidine—Myalgia—Docetaxel—breast cancer	0.000368	0.000449	CcSEcCtD
Apraclonidine—Chest pain—Docetaxel—breast cancer	0.000368	0.000449	CcSEcCtD
Apraclonidine—Nausea—Vinorelbine—breast cancer	0.000367	0.000449	CcSEcCtD
Apraclonidine—Asthenia—Irinotecan—breast cancer	0.000366	0.000447	CcSEcCtD
Apraclonidine—Asthenia—Mitoxantrone—breast cancer	0.000366	0.000447	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	0.000365	0.000446	CcSEcCtD
Apraclonidine—Conjunctivitis—Epirubicin—breast cancer	0.000362	0.000443	CcSEcCtD
Apraclonidine—Hypersensitivity—Fluorouracil—breast cancer	0.00036	0.00044	CcSEcCtD
Apraclonidine—Dry mouth—Docetaxel—breast cancer	0.00036	0.000439	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000359	0.000439	CcSEcCtD
Apraclonidine—Fatigue—Paclitaxel—breast cancer	0.000359	0.000438	CcSEcCtD
Apraclonidine—Haemorrhage—Methotrexate—breast cancer	0.000358	0.000437	CcSEcCtD
Apraclonidine—Asthenia—Gemcitabine—breast cancer	0.000357	0.000435	CcSEcCtD
Apraclonidine—Chest pain—Capecitabine—breast cancer	0.000356	0.000435	CcSEcCtD
Apraclonidine—Myalgia—Capecitabine—breast cancer	0.000356	0.000435	CcSEcCtD
Apraclonidine—Pain—Paclitaxel—breast cancer	0.000356	0.000435	CcSEcCtD
Apraclonidine—Constipation—Paclitaxel—breast cancer	0.000356	0.000435	CcSEcCtD
Apraclonidine—Pharyngitis—Methotrexate—breast cancer	0.000355	0.000434	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	0.000354	0.000432	CcSEcCtD
Apraclonidine—Oedema—Docetaxel—breast cancer	0.000353	0.000431	CcSEcCtD
Apraclonidine—Discomfort—Capecitabine—breast cancer	0.000352	0.00043	CcSEcCtD
Apraclonidine—Pruritus—Gemcitabine—breast cancer	0.000352	0.000429	CcSEcCtD
Apraclonidine—Nausea—Thiotepa—breast cancer	0.000351	0.000429	CcSEcCtD
Apraclonidine—Infection—Docetaxel—breast cancer	0.00035	0.000428	CcSEcCtD
Apraclonidine—Diarrhoea—Mitoxantrone—breast cancer	0.000349	0.000426	CcSEcCtD
Apraclonidine—Diarrhoea—Irinotecan—breast cancer	0.000349	0.000426	CcSEcCtD
Apraclonidine—Dry mouth—Capecitabine—breast cancer	0.000348	0.000425	CcSEcCtD
Apraclonidine—Nervous system disorder—Docetaxel—breast cancer	0.000346	0.000422	CcSEcCtD
Apraclonidine—Pruritus—Fluorouracil—breast cancer	0.000346	0.000422	CcSEcCtD
Apraclonidine—Infestation NOS—Doxorubicin—breast cancer	0.000345	0.000421	CcSEcCtD
Apraclonidine—Infestation—Doxorubicin—breast cancer	0.000345	0.000421	CcSEcCtD
Apraclonidine—Visual impairment—Methotrexate—breast cancer	0.000345	0.000421	CcSEcCtD
Apraclonidine—Feeling abnormal—Paclitaxel—breast cancer	0.000343	0.000419	CcSEcCtD
Apraclonidine—Skin disorder—Docetaxel—breast cancer	0.000343	0.000418	CcSEcCtD
Apraclonidine—Oedema—Capecitabine—breast cancer	0.000341	0.000417	CcSEcCtD
Apraclonidine—Bradycardia—Epirubicin—breast cancer	0.000341	0.000416	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Paclitaxel—breast cancer	0.00034	0.000416	CcSEcCtD
Apraclonidine—Diarrhoea—Gemcitabine—breast cancer	0.00034	0.000415	CcSEcCtD
Apraclonidine—Infection—Capecitabine—breast cancer	0.000339	0.000414	CcSEcCtD
Apraclonidine—Dizziness—Irinotecan—breast cancer	0.000337	0.000412	CcSEcCtD
Apraclonidine—Rhinitis—Epirubicin—breast cancer	0.000336	0.00041	CcSEcCtD
Apraclonidine—Conjunctivitis—Doxorubicin—breast cancer	0.000335	0.00041	CcSEcCtD
Apraclonidine—Nervous system disorder—Capecitabine—breast cancer	0.000335	0.000409	CcSEcCtD
Apraclonidine—Haemorrhage—Epirubicin—breast cancer	0.000335	0.000409	CcSEcCtD
Apraclonidine—Eye disorder—Methotrexate—breast cancer	0.000334	0.000408	CcSEcCtD
Apraclonidine—Diarrhoea—Fluorouracil—breast cancer	0.000334	0.000408	CcSEcCtD
Apraclonidine—Pharyngitis—Epirubicin—breast cancer	0.000332	0.000406	CcSEcCtD
Apraclonidine—Skin disorder—Capecitabine—breast cancer	0.000332	0.000405	CcSEcCtD
Apraclonidine—Oedema peripheral—Epirubicin—breast cancer	0.00033	0.000403	CcSEcCtD
Apraclonidine—Abdominal pain—Paclitaxel—breast cancer	0.000329	0.000402	CcSEcCtD
Apraclonidine—Angiopathy—Methotrexate—breast cancer	0.000325	0.000396	CcSEcCtD
Apraclonidine—Vomiting—Irinotecan—breast cancer	0.000324	0.000396	CcSEcCtD
Apraclonidine—Vomiting—Mitoxantrone—breast cancer	0.000324	0.000396	CcSEcCtD
Apraclonidine—Dizziness—Fluorouracil—breast cancer	0.000323	0.000395	CcSEcCtD
Apraclonidine—Visual impairment—Epirubicin—breast cancer	0.000323	0.000394	CcSEcCtD
Apraclonidine—Mediastinal disorder—Methotrexate—breast cancer	0.000322	0.000394	CcSEcCtD
Apraclonidine—Dermatitis—Irinotecan—breast cancer	0.000321	0.000392	CcSEcCtD
Apraclonidine—Dermatitis—Mitoxantrone—breast cancer	0.000321	0.000392	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Docetaxel—breast cancer	0.000321	0.000392	CcSEcCtD
Apraclonidine—Headache—Mitoxantrone—breast cancer	0.00032	0.00039	CcSEcCtD
Apraclonidine—Headache—Irinotecan—breast cancer	0.00032	0.00039	CcSEcCtD
Apraclonidine—Insomnia—Docetaxel—breast cancer	0.000319	0.00039	CcSEcCtD
Apraclonidine—Paraesthesia—Docetaxel—breast cancer	0.000317	0.000387	CcSEcCtD
Apraclonidine—Vomiting—Gemcitabine—breast cancer	0.000316	0.000386	CcSEcCtD
Apraclonidine—Bradycardia—Doxorubicin—breast cancer	0.000315	0.000385	CcSEcCtD
Apraclonidine—Dyspnoea—Docetaxel—breast cancer	0.000314	0.000384	CcSEcCtD
Apraclonidine—Somnolence—Docetaxel—breast cancer	0.000313	0.000383	CcSEcCtD
Apraclonidine—Mental disorder—Methotrexate—breast cancer	0.000313	0.000383	CcSEcCtD
Apraclonidine—Dermatitis—Gemcitabine—breast cancer	0.000313	0.000382	CcSEcCtD
Apraclonidine—Eye disorder—Epirubicin—breast cancer	0.000313	0.000382	CcSEcCtD
Apraclonidine—Erythema—Methotrexate—breast cancer	0.000311	0.00038	CcSEcCtD
Apraclonidine—Headache—Gemcitabine—breast cancer	0.000311	0.00038	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Capecitabine—breast cancer	0.000311	0.00038	CcSEcCtD
Apraclonidine—Vomiting—Fluorouracil—breast cancer	0.000311	0.000379	CcSEcCtD
Apraclonidine—Rhinitis—Doxorubicin—breast cancer	0.000311	0.000379	CcSEcCtD
Apraclonidine—Haemorrhage—Doxorubicin—breast cancer	0.00031	0.000378	CcSEcCtD
Apraclonidine—Insomnia—Capecitabine—breast cancer	0.000309	0.000377	CcSEcCtD
Apraclonidine—Dermatitis—Fluorouracil—breast cancer	0.000308	0.000376	CcSEcCtD
Apraclonidine—Pharyngitis—Doxorubicin—breast cancer	0.000307	0.000376	CcSEcCtD
Apraclonidine—Paraesthesia—Capecitabine—breast cancer	0.000307	0.000374	CcSEcCtD
Apraclonidine—Hypersensitivity—Paclitaxel—breast cancer	0.000307	0.000374	CcSEcCtD
Apraclonidine—Headache—Fluorouracil—breast cancer	0.000306	0.000374	CcSEcCtD
Apraclonidine—Oedema peripheral—Doxorubicin—breast cancer	0.000305	0.000373	CcSEcCtD
Apraclonidine—Dysgeusia—Methotrexate—breast cancer	0.000305	0.000372	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Docetaxel—breast cancer	0.000304	0.000372	CcSEcCtD
Apraclonidine—Dyspnoea—Capecitabine—breast cancer	0.000304	0.000372	CcSEcCtD
Apraclonidine—Fatigue—Docetaxel—breast cancer	0.000304	0.000371	CcSEcCtD
Apraclonidine—Angiopathy—Epirubicin—breast cancer	0.000304	0.000371	CcSEcCtD
Apraclonidine—Nausea—Irinotecan—breast cancer	0.000303	0.00037	CcSEcCtD
Apraclonidine—Nausea—Mitoxantrone—breast cancer	0.000303	0.00037	CcSEcCtD
Apraclonidine—Mediastinal disorder—Epirubicin—breast cancer	0.000302	0.000369	CcSEcCtD
Apraclonidine—Pain—Docetaxel—breast cancer	0.000302	0.000368	CcSEcCtD
Apraclonidine—Constipation—Docetaxel—breast cancer	0.000302	0.000368	CcSEcCtD
Apraclonidine—Arrhythmia—Epirubicin—breast cancer	0.000299	0.000365	CcSEcCtD
Apraclonidine—Visual impairment—Doxorubicin—breast cancer	0.000299	0.000365	CcSEcCtD
Apraclonidine—Asthenia—Paclitaxel—breast cancer	0.000298	0.000365	CcSEcCtD
Apraclonidine—Nausea—Gemcitabine—breast cancer	0.000295	0.000361	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Capecitabine—breast cancer	0.000295	0.00036	CcSEcCtD
Apraclonidine—Fatigue—Capecitabine—breast cancer	0.000294	0.00036	CcSEcCtD
Apraclonidine—Pruritus—Paclitaxel—breast cancer	0.000294	0.00036	CcSEcCtD
Apraclonidine—Vision blurred—Methotrexate—breast cancer	0.000293	0.000358	CcSEcCtD
Apraclonidine—Mental disorder—Epirubicin—breast cancer	0.000293	0.000358	CcSEcCtD
Apraclonidine—Constipation—Capecitabine—breast cancer	0.000292	0.000357	CcSEcCtD
Apraclonidine—Pain—Capecitabine—breast cancer	0.000292	0.000357	CcSEcCtD
Apraclonidine—Erythema—Epirubicin—breast cancer	0.000291	0.000356	CcSEcCtD
Apraclonidine—Feeling abnormal—Docetaxel—breast cancer	0.000291	0.000355	CcSEcCtD
Apraclonidine—Nausea—Fluorouracil—breast cancer	0.00029	0.000354	CcSEcCtD
Apraclonidine—Eye disorder—Doxorubicin—breast cancer	0.000289	0.000354	CcSEcCtD
Apraclonidine—Ill-defined disorder—Methotrexate—breast cancer	0.000289	0.000353	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Docetaxel—breast cancer	0.000288	0.000352	CcSEcCtD
Apraclonidine—Tension—Epirubicin—breast cancer	0.000286	0.000349	CcSEcCtD
Apraclonidine—Dysgeusia—Epirubicin—breast cancer	0.000285	0.000349	CcSEcCtD
Apraclonidine—Diarrhoea—Paclitaxel—breast cancer	0.000285	0.000348	CcSEcCtD
Apraclonidine—Nervousness—Epirubicin—breast cancer	0.000283	0.000346	CcSEcCtD
Apraclonidine—Feeling abnormal—Capecitabine—breast cancer	0.000281	0.000344	CcSEcCtD
Apraclonidine—Angiopathy—Doxorubicin—breast cancer	0.000281	0.000343	CcSEcCtD
Apraclonidine—Malaise—Methotrexate—breast cancer	0.000281	0.000343	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Capecitabine—breast cancer	0.000279	0.000341	CcSEcCtD
Apraclonidine—Mediastinal disorder—Doxorubicin—breast cancer	0.000279	0.000341	CcSEcCtD
Apraclonidine—Abdominal pain—Docetaxel—breast cancer	0.000279	0.00034	CcSEcCtD
Apraclonidine—Arrhythmia—Doxorubicin—breast cancer	0.000277	0.000338	CcSEcCtD
Apraclonidine—Dizziness—Paclitaxel—breast cancer	0.000275	0.000336	CcSEcCtD
Apraclonidine—Vision blurred—Epirubicin—breast cancer	0.000275	0.000335	CcSEcCtD
Apraclonidine—Mental disorder—Doxorubicin—breast cancer	0.000271	0.000331	CcSEcCtD
Apraclonidine—Ill-defined disorder—Epirubicin—breast cancer	0.00027	0.00033	CcSEcCtD
Apraclonidine—Abdominal pain—Capecitabine—breast cancer	0.00027	0.00033	CcSEcCtD
Apraclonidine—Erythema—Doxorubicin—breast cancer	0.00027	0.000329	CcSEcCtD
Apraclonidine—Chest pain—Methotrexate—breast cancer	0.000265	0.000324	CcSEcCtD
Apraclonidine—Myalgia—Methotrexate—breast cancer	0.000265	0.000324	CcSEcCtD
Apraclonidine—Tension—Doxorubicin—breast cancer	0.000265	0.000323	CcSEcCtD
Apraclonidine—Vomiting—Paclitaxel—breast cancer	0.000265	0.000323	CcSEcCtD
Apraclonidine—Dysgeusia—Doxorubicin—breast cancer	0.000264	0.000323	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	0.000263	0.000322	CcSEcCtD
Apraclonidine—Malaise—Epirubicin—breast cancer	0.000263	0.000321	CcSEcCtD
Apraclonidine—Dermatitis—Paclitaxel—breast cancer	0.000262	0.00032	CcSEcCtD
Apraclonidine—Discomfort—Methotrexate—breast cancer	0.000262	0.00032	CcSEcCtD
Apraclonidine—Nervousness—Doxorubicin—breast cancer	0.000262	0.00032	CcSEcCtD
Apraclonidine—Syncope—Epirubicin—breast cancer	0.000261	0.000319	CcSEcCtD
Apraclonidine—Headache—Paclitaxel—breast cancer	0.000261	0.000318	CcSEcCtD
Apraclonidine—Hypersensitivity—Docetaxel—breast cancer	0.00026	0.000317	CcSEcCtD
Apraclonidine—Palpitations—Epirubicin—breast cancer	0.000258	0.000315	CcSEcCtD
Apraclonidine—Vision blurred—Doxorubicin—breast cancer	0.000254	0.00031	CcSEcCtD
Apraclonidine—Asthenia—Docetaxel—breast cancer	0.000253	0.000309	CcSEcCtD
Apraclonidine—Infection—Methotrexate—breast cancer	0.000252	0.000308	CcSEcCtD
Apraclonidine—Hypersensitivity—Capecitabine—breast cancer	0.000252	0.000307	CcSEcCtD
Apraclonidine—Ill-defined disorder—Doxorubicin—breast cancer	0.00025	0.000306	CcSEcCtD
Apraclonidine—Pruritus—Docetaxel—breast cancer	0.000249	0.000305	CcSEcCtD
Apraclonidine—Nervous system disorder—Methotrexate—breast cancer	0.000249	0.000304	CcSEcCtD
Apraclonidine—Chest pain—Epirubicin—breast cancer	0.000248	0.000303	CcSEcCtD
Apraclonidine—Myalgia—Epirubicin—breast cancer	0.000248	0.000303	CcSEcCtD
Apraclonidine—Nausea—Paclitaxel—breast cancer	0.000247	0.000302	CcSEcCtD
Apraclonidine—Skin disorder—Methotrexate—breast cancer	0.000247	0.000302	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	0.000246	0.000301	CcSEcCtD
Apraclonidine—Discomfort—Epirubicin—breast cancer	0.000245	0.000299	CcSEcCtD
Apraclonidine—Asthenia—Capecitabine—breast cancer	0.000245	0.000299	CcSEcCtD
Apraclonidine—Malaise—Doxorubicin—breast cancer	0.000243	0.000297	CcSEcCtD
Apraclonidine—Dry mouth—Epirubicin—breast cancer	0.000243	0.000296	CcSEcCtD
Apraclonidine—Syncope—Doxorubicin—breast cancer	0.000242	0.000295	CcSEcCtD
Apraclonidine—Pruritus—Capecitabine—breast cancer	0.000242	0.000295	CcSEcCtD
Apraclonidine—Diarrhoea—Docetaxel—breast cancer	0.000241	0.000295	CcSEcCtD
Apraclonidine—Palpitations—Doxorubicin—breast cancer	0.000238	0.000291	CcSEcCtD
Apraclonidine—Oedema—Epirubicin—breast cancer	0.000238	0.000291	CcSEcCtD
Apraclonidine—Infection—Epirubicin—breast cancer	0.000236	0.000289	CcSEcCtD
Apraclonidine—Diarrhoea—Capecitabine—breast cancer	0.000234	0.000285	CcSEcCtD
Apraclonidine—Nervous system disorder—Epirubicin—breast cancer	0.000233	0.000285	CcSEcCtD
Apraclonidine—Dizziness—Docetaxel—breast cancer	0.000233	0.000285	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Methotrexate—breast cancer	0.000232	0.000283	CcSEcCtD
Apraclonidine—Skin disorder—Epirubicin—breast cancer	0.000231	0.000282	CcSEcCtD
Apraclonidine—Insomnia—Methotrexate—breast cancer	0.00023	0.000281	CcSEcCtD
Apraclonidine—Myalgia—Doxorubicin—breast cancer	0.00023	0.00028	CcSEcCtD
Apraclonidine—Chest pain—Doxorubicin—breast cancer	0.00023	0.00028	CcSEcCtD
Apraclonidine—Paraesthesia—Methotrexate—breast cancer	0.000228	0.000279	CcSEcCtD
Apraclonidine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	0.000228	0.000278	CcSEcCtD
Apraclonidine—Discomfort—Doxorubicin—breast cancer	0.000227	0.000277	CcSEcCtD
Apraclonidine—Dyspnoea—Methotrexate—breast cancer	0.000227	0.000277	CcSEcCtD
Apraclonidine—Somnolence—Methotrexate—breast cancer	0.000226	0.000276	CcSEcCtD
Apraclonidine—Dizziness—Capecitabine—breast cancer	0.000226	0.000276	CcSEcCtD
Apraclonidine—Dry mouth—Doxorubicin—breast cancer	0.000225	0.000274	CcSEcCtD
Apraclonidine—Vomiting—Docetaxel—breast cancer	0.000224	0.000274	CcSEcCtD
Apraclonidine—Dermatitis—Docetaxel—breast cancer	0.000222	0.000271	CcSEcCtD
Apraclonidine—Headache—Docetaxel—breast cancer	0.000221	0.00027	CcSEcCtD
Apraclonidine—Oedema—Doxorubicin—breast cancer	0.00022	0.000269	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Methotrexate—breast cancer	0.000219	0.000268	CcSEcCtD
Apraclonidine—Fatigue—Methotrexate—breast cancer	0.000219	0.000268	CcSEcCtD
Apraclonidine—Infection—Doxorubicin—breast cancer	0.000219	0.000267	CcSEcCtD
Apraclonidine—Pain—Methotrexate—breast cancer	0.000217	0.000265	CcSEcCtD
Apraclonidine—Vomiting—Capecitabine—breast cancer	0.000217	0.000265	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Epirubicin—breast cancer	0.000217	0.000265	CcSEcCtD
Apraclonidine—Nervous system disorder—Doxorubicin—breast cancer	0.000216	0.000264	CcSEcCtD
Apraclonidine—Insomnia—Epirubicin—breast cancer	0.000215	0.000263	CcSEcCtD
Apraclonidine—Dermatitis—Capecitabine—breast cancer	0.000215	0.000263	CcSEcCtD
Apraclonidine—Headache—Capecitabine—breast cancer	0.000214	0.000261	CcSEcCtD
Apraclonidine—Skin disorder—Doxorubicin—breast cancer	0.000214	0.000261	CcSEcCtD
Apraclonidine—Paraesthesia—Epirubicin—breast cancer	0.000214	0.000261	CcSEcCtD
Apraclonidine—Dyspnoea—Epirubicin—breast cancer	0.000212	0.000259	CcSEcCtD
Apraclonidine—Somnolence—Epirubicin—breast cancer	0.000211	0.000258	CcSEcCtD
Apraclonidine—Nausea—Docetaxel—breast cancer	0.000209	0.000256	CcSEcCtD
Apraclonidine—Feeling abnormal—Methotrexate—breast cancer	0.000209	0.000256	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Methotrexate—breast cancer	0.000208	0.000254	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Epirubicin—breast cancer	0.000205	0.000251	CcSEcCtD
Apraclonidine—Fatigue—Epirubicin—breast cancer	0.000205	0.00025	CcSEcCtD
Apraclonidine—Pain—Epirubicin—breast cancer	0.000203	0.000248	CcSEcCtD
Apraclonidine—Constipation—Epirubicin—breast cancer	0.000203	0.000248	CcSEcCtD
Apraclonidine—Nausea—Capecitabine—breast cancer	0.000203	0.000248	CcSEcCtD
Apraclonidine—Abdominal pain—Methotrexate—breast cancer	0.000201	0.000245	CcSEcCtD
Apraclonidine—Musculoskeletal discomfort—Doxorubicin—breast cancer	0.000201	0.000245	CcSEcCtD
Apraclonidine—Insomnia—Doxorubicin—breast cancer	0.000199	0.000243	CcSEcCtD
Apraclonidine—Paraesthesia—Doxorubicin—breast cancer	0.000198	0.000241	CcSEcCtD
Apraclonidine—Dyspnoea—Doxorubicin—breast cancer	0.000196	0.00024	CcSEcCtD
Apraclonidine—Feeling abnormal—Epirubicin—breast cancer	0.000196	0.000239	CcSEcCtD
Apraclonidine—Somnolence—Doxorubicin—breast cancer	0.000196	0.000239	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Epirubicin—breast cancer	0.000194	0.000238	CcSEcCtD
Apraclonidine—Gastrointestinal disorder—Doxorubicin—breast cancer	0.00019	0.000232	CcSEcCtD
Apraclonidine—Fatigue—Doxorubicin—breast cancer	0.00019	0.000232	CcSEcCtD
Apraclonidine—Pain—Doxorubicin—breast cancer	0.000188	0.00023	CcSEcCtD
Apraclonidine—Constipation—Doxorubicin—breast cancer	0.000188	0.00023	CcSEcCtD
Apraclonidine—Abdominal pain—Epirubicin—breast cancer	0.000188	0.00023	CcSEcCtD
Apraclonidine—Hypersensitivity—Methotrexate—breast cancer	0.000187	0.000229	CcSEcCtD
Apraclonidine—Asthenia—Methotrexate—breast cancer	0.000182	0.000223	CcSEcCtD
Apraclonidine—Feeling abnormal—Doxorubicin—breast cancer	0.000181	0.000222	CcSEcCtD
Apraclonidine—Gastrointestinal pain—Doxorubicin—breast cancer	0.00018	0.00022	CcSEcCtD
Apraclonidine—Pruritus—Methotrexate—breast cancer	0.00018	0.00022	CcSEcCtD
Apraclonidine—Hypersensitivity—Epirubicin—breast cancer	0.000175	0.000214	CcSEcCtD
Apraclonidine—Abdominal pain—Doxorubicin—breast cancer	0.000174	0.000212	CcSEcCtD
Apraclonidine—Diarrhoea—Methotrexate—breast cancer	0.000174	0.000212	CcSEcCtD
Apraclonidine—Asthenia—Epirubicin—breast cancer	0.000171	0.000208	CcSEcCtD
Apraclonidine—Pruritus—Epirubicin—breast cancer	0.000168	0.000206	CcSEcCtD
Apraclonidine—Dizziness—Methotrexate—breast cancer	0.000168	0.000205	CcSEcCtD
Apraclonidine—Diarrhoea—Epirubicin—breast cancer	0.000163	0.000199	CcSEcCtD
Apraclonidine—Hypersensitivity—Doxorubicin—breast cancer	0.000162	0.000198	CcSEcCtD
Apraclonidine—Vomiting—Methotrexate—breast cancer	0.000162	0.000197	CcSEcCtD
Apraclonidine—Dermatitis—Methotrexate—breast cancer	0.00016	0.000196	CcSEcCtD
Apraclonidine—Headache—Methotrexate—breast cancer	0.000159	0.000194	CcSEcCtD
Apraclonidine—Asthenia—Doxorubicin—breast cancer	0.000158	0.000193	CcSEcCtD
Apraclonidine—Dizziness—Epirubicin—breast cancer	0.000157	0.000192	CcSEcCtD
Apraclonidine—Pruritus—Doxorubicin—breast cancer	0.000156	0.00019	CcSEcCtD
Apraclonidine—Vomiting—Epirubicin—breast cancer	0.000151	0.000185	CcSEcCtD
Apraclonidine—Nausea—Methotrexate—breast cancer	0.000151	0.000184	CcSEcCtD
Apraclonidine—Diarrhoea—Doxorubicin—breast cancer	0.000151	0.000184	CcSEcCtD
Apraclonidine—Dermatitis—Epirubicin—breast cancer	0.00015	0.000183	CcSEcCtD
Apraclonidine—Headache—Epirubicin—breast cancer	0.000149	0.000182	CcSEcCtD
Apraclonidine—Dizziness—Doxorubicin—breast cancer	0.000146	0.000178	CcSEcCtD
Apraclonidine—Nausea—Epirubicin—breast cancer	0.000141	0.000173	CcSEcCtD
Apraclonidine—Vomiting—Doxorubicin—breast cancer	0.00014	0.000171	CcSEcCtD
Apraclonidine—Dermatitis—Doxorubicin—breast cancer	0.000139	0.000169	CcSEcCtD
Apraclonidine—Headache—Doxorubicin—breast cancer	0.000138	0.000168	CcSEcCtD
Apraclonidine—Nausea—Doxorubicin—breast cancer	0.000131	0.00016	CcSEcCtD
Apraclonidine—ADRA2B—Signaling Pathways—APC—breast cancer	2.64e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CG—breast cancer	2.64e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KIT—breast cancer	2.64e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—CAV1—breast cancer	2.63e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—H2AFX—breast cancer	2.63e-05	0.000149	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—IL2—breast cancer	2.63e-05	0.000148	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—E2F1—breast cancer	2.61e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGF—breast cancer	2.61e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ESR1—breast cancer	2.61e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CB—breast cancer	2.6e-05	0.000147	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CD—breast cancer	2.59e-05	0.000146	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—FN1—breast cancer	2.58e-05	0.000146	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL2—breast cancer	2.57e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—ALB—breast cancer	2.56e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TERT—breast cancer	2.56e-05	0.000145	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—HRAS—breast cancer	2.55e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NFKBIA—breast cancer	2.55e-05	0.000144	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—MAPK3—breast cancer	2.53e-05	0.000143	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOTCH1—breast cancer	2.52e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SPP1—breast cancer	2.51e-05	0.000142	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—CXCL8—breast cancer	2.5e-05	0.000141	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FGFR1—breast cancer	2.49e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—BRAF—breast cancer	2.48e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ERBB3—breast cancer	2.48e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGFR2—breast cancer	2.48e-05	0.00014	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CG—breast cancer	2.47e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KIT—breast cancer	2.47e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—APC—breast cancer	2.47e-05	0.000139	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—NOS3—breast cancer	2.45e-05	0.000138	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HIF1A—breast cancer	2.45e-05	0.000138	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGF—breast cancer	2.44e-05	0.000138	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IGF1—breast cancer	2.42e-05	0.000137	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT2—breast cancer	2.42e-05	0.000136	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—EGFR—breast cancer	2.41e-05	0.000136	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CG—breast cancer	2.4e-05	0.000135	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—LEP—breast cancer	2.39e-05	0.000135	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL2—breast cancer	2.39e-05	0.000135	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TERT—breast cancer	2.38e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CAV1—breast cancer	2.37e-05	0.000134	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—MAPK3—breast cancer	2.36e-05	0.000133	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KDR—breast cancer	2.34e-05	0.000132	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CD—breast cancer	2.32e-05	0.000131	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—BRAF—breast cancer	2.32e-05	0.000131	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FGFR1—breast cancer	2.31e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—PIK3CA—breast cancer	2.3e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SERPINE1—breast cancer	2.3e-05	0.00013	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ESR1—breast cancer	2.28e-05	0.000129	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HIF1A—breast cancer	2.28e-05	0.000128	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—KRAS—breast cancer	2.27e-05	0.000128	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CB—breast cancer	2.26e-05	0.000128	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IGF1—breast cancer	2.26e-05	0.000128	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT2—breast cancer	2.26e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2A—Hemostasis—AKT1—breast cancer	2.26e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—FN1—breast cancer	2.25e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—EGFR—breast cancer	2.25e-05	0.000127	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTGS2—breast cancer	2.24e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NFKBIA—breast cancer	2.23e-05	0.000126	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—LEP—breast cancer	2.22e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOTCH1—breast cancer	2.21e-05	0.000125	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CAV1—breast cancer	2.2e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—NOS3—breast cancer	2.19e-05	0.000124	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KDR—breast cancer	2.18e-05	0.000123	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CD—breast cancer	2.17e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—APC—breast cancer	2.16e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CG—breast cancer	2.16e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KIT—breast cancer	2.16e-05	0.000122	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—PIK3CA—breast cancer	2.15e-05	0.000121	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SERPINE1—breast cancer	2.15e-05	0.000121	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGF—breast cancer	2.13e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—KRAS—breast cancer	2.12e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ESR1—breast cancer	2.12e-05	0.00012	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CD—breast cancer	2.11e-05	0.000119	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—FN1—breast cancer	2.09e-05	0.000118	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—PIK3CA—breast cancer	2.09e-05	0.000118	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MDM2—breast cancer	2.08e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—ALB—breast cancer	2.08e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RAF1—breast cancer	2.07e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NFKBIA—breast cancer	2.07e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—MAPK3—breast cancer	2.07e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—RELA—breast cancer	2.06e-05	0.000117	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—ERBB2—breast cancer	2.05e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOTCH1—breast cancer	2.05e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—NOS3—breast cancer	2.05e-05	0.000116	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—BRAF—breast cancer	2.03e-05	0.000114	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MTOR—breast cancer	2.02e-05	0.000114	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CB—breast cancer	2.02e-05	0.000114	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CG—breast cancer	2e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KIT—breast cancer	2e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—APC—breast cancer	2e-05	0.000113	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—NOS3—breast cancer	1.99e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGF—breast cancer	1.98e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IGF1—breast cancer	1.98e-05	0.000112	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT2—breast cancer	1.97e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—EGFR—breast cancer	1.97e-05	0.000111	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PTEN—breast cancer	1.95e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—PIK3CA—breast cancer	1.95e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CXCL8—breast cancer	1.95e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MDM2—breast cancer	1.94e-05	0.00011	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RAF1—breast cancer	1.94e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—HRAS—breast cancer	1.93e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—RELA—breast cancer	1.93e-05	0.000109	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—MAPK3—breast cancer	1.92e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—ERBB2—breast cancer	1.92e-05	0.000108	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN1B—breast cancer	1.9e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CD—breast cancer	1.9e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CB—breast cancer	1.89e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MTOR—breast cancer	1.89e-05	0.000107	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—BRAF—breast cancer	1.88e-05	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2B—GPCR downstream signaling—AKT1—breast cancer	1.88e-05	0.000106	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—PIK3CA—breast cancer	1.88e-05	0.000106	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SERPINE1—breast cancer	1.88e-05	0.000106	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CASP3—breast cancer	1.86e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL2—breast cancer	1.86e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—KRAS—breast cancer	1.86e-05	0.000105	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—IL6—breast cancer	1.85e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CB—breast cancer	1.84e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IGF1—breast cancer	1.84e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT2—breast cancer	1.83e-05	0.000104	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—EGFR—breast cancer	1.83e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTGS2—breast cancer	1.82e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CXCL8—breast cancer	1.82e-05	0.000103	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CCND1—breast cancer	1.81e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—JUN—breast cancer	1.81e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—HRAS—breast cancer	1.81e-05	0.000102	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CTNNB1—breast cancer	1.79e-05	0.000101	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—NOS3—breast cancer	1.79e-05	0.000101	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN1B—breast cancer	1.77e-05	0.0001	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CD—breast cancer	1.76e-05	9.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MMP9—breast cancer	1.76e-05	9.93e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—GPCR downstream signaling—AKT1—breast cancer	1.76e-05	9.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—CDKN1A—breast cancer	1.75e-05	9.9e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PTEN—breast cancer	1.75e-05	9.87e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—PIK3CA—breast cancer	1.75e-05	9.85e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SERPINE1—breast cancer	1.74e-05	9.84e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CASP3—breast cancer	1.74e-05	9.82e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL2—breast cancer	1.74e-05	9.8e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—IL6—breast cancer	1.73e-05	9.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—KRAS—breast cancer	1.73e-05	9.74e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK8—breast cancer	1.71e-05	9.66e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling by GPCR—AKT1—breast cancer	1.71e-05	9.63e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—PIK3CA—breast cancer	1.71e-05	9.63e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MDM2—breast cancer	1.7e-05	9.59e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RAF1—breast cancer	1.69e-05	9.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CCND1—breast cancer	1.69e-05	9.56e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—JUN—breast cancer	1.69e-05	9.54e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—RELA—breast cancer	1.69e-05	9.52e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CTNNB1—breast cancer	1.68e-05	9.46e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—ERBB2—breast cancer	1.67e-05	9.46e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—NOS3—breast cancer	1.66e-05	9.39e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MTOR—breast cancer	1.65e-05	9.33e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CB—breast cancer	1.65e-05	9.33e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MMP9—breast cancer	1.64e-05	9.28e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—CDKN1A—breast cancer	1.64e-05	9.24e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PTEN—breast cancer	1.63e-05	9.22e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—SRC—breast cancer	1.62e-05	9.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK8—breast cancer	1.6e-05	9.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling by GPCR—AKT1—breast cancer	1.59e-05	9e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CXCL8—breast cancer	1.59e-05	8.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PTEN—breast cancer	1.59e-05	8.96e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	1.58e-05	8.95e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—VEGFA—breast cancer	1.58e-05	8.92e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MDM2—breast cancer	1.58e-05	8.91e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—HRAS—breast cancer	1.58e-05	8.91e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RAF1—breast cancer	1.57e-05	8.88e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—RELA—breast cancer	1.57e-05	8.84e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—STAT3—breast cancer	1.56e-05	8.83e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—ERBB2—breast cancer	1.56e-05	8.79e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	1.55e-05	8.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MTOR—breast cancer	1.54e-05	8.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	1.54e-05	8.67e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	1.53e-05	8.66e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CASP3—breast cancer	1.52e-05	8.58e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL2—breast cancer	1.52e-05	8.57e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—SRC—breast cancer	1.52e-05	8.55e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—IL6—breast cancer	1.51e-05	8.53e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MAPK3—breast cancer	1.49e-05	8.44e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CCND1—breast cancer	1.48e-05	8.35e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—JUN—breast cancer	1.48e-05	8.34e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CXCL8—breast cancer	1.48e-05	8.33e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—VEGFA—breast cancer	1.48e-05	8.33e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—HRAS—breast cancer	1.47e-05	8.28e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	1.47e-05	8.27e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—STAT3—breast cancer	1.46e-05	8.25e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—MYC—breast cancer	1.45e-05	8.21e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TGFB1—breast cancer	1.45e-05	8.19e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	1.44e-05	8.14e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MMP9—breast cancer	1.44e-05	8.11e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	1.43e-05	8.08e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PTEN—breast cancer	1.43e-05	8.06e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	1.43e-05	8.05e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—EGFR—breast cancer	1.42e-05	8.03e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CASP3—breast cancer	1.41e-05	7.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL2—breast cancer	1.41e-05	7.96e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—IL6—breast cancer	1.4e-05	7.92e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK8—breast cancer	1.4e-05	7.89e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MAPK3—breast cancer	1.4e-05	7.88e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling by GPCR—AKT1—breast cancer	1.39e-05	7.87e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—PIK3CA—breast cancer	1.38e-05	7.78e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CCND1—breast cancer	1.37e-05	7.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—JUN—breast cancer	1.37e-05	7.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	1.36e-05	7.69e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—MYC—breast cancer	1.36e-05	7.67e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TGFB1—breast cancer	1.35e-05	7.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—KRAS—breast cancer	1.34e-05	7.58e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MMP9—breast cancer	1.33e-05	7.54e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	1.33e-05	7.51e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—EGFR—breast cancer	1.33e-05	7.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PTEN—breast cancer	1.33e-05	7.49e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—SRC—breast cancer	1.32e-05	7.48e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK8—breast cancer	1.3e-05	7.33e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling by GPCR—AKT1—breast cancer	1.29e-05	7.31e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—VEGFA—breast cancer	1.29e-05	7.28e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—STAT3—breast cancer	1.28e-05	7.21e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—KRAS—breast cancer	1.25e-05	7.08e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—PIK3CA—breast cancer	1.23e-05	6.97e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—SRC—breast cancer	1.23e-05	6.95e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MAPK3—breast cancer	1.22e-05	6.89e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—VEGFA—breast cancer	1.2e-05	6.77e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—TP53—breast cancer	1.19e-05	6.74e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—MYC—breast cancer	1.19e-05	6.7e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—STAT3—breast cancer	1.19e-05	6.7e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TGFB1—breast cancer	1.18e-05	6.68e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—EGFR—breast cancer	1.16e-05	6.55e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—PIK3CA—breast cancer	1.15e-05	6.51e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—HRAS—breast cancer	1.14e-05	6.45e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MAPK3—breast cancer	1.13e-05	6.4e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Metabolism—AKT1—breast cancer	1.13e-05	6.36e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—PIK3CA—breast cancer	1.12e-05	6.32e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—TP53—breast cancer	1.12e-05	6.3e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—MYC—breast cancer	1.1e-05	6.23e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TGFB1—breast cancer	1.1e-05	6.21e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—KRAS—breast cancer	1.1e-05	6.19e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—IL6—breast cancer	1.09e-05	6.17e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—EGFR—breast cancer	1.08e-05	6.09e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—HRAS—breast cancer	1.07e-05	6.02e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—IL6—breast cancer	1.02e-05	5.76e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—KRAS—breast cancer	1.02e-05	5.75e-05	CbGpPWpGaD
Apraclonidine—ADRA2B—Signaling Pathways—AKT1—breast cancer	1.01e-05	5.69e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	1.01e-05	5.69e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—TP53—breast cancer	9.75e-06	5.5e-05	CbGpPWpGaD
Apraclonidine—ADRA2C—Signaling Pathways—AKT1—breast cancer	9.42e-06	5.32e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	9.36e-06	5.29e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—HRAS—breast cancer	9.32e-06	5.26e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Metabolism—AKT1—breast cancer	9.15e-06	5.16e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—TP53—breast cancer	9.06e-06	5.11e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—IL6—breast cancer	8.92e-06	5.04e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—HRAS—breast cancer	8.66e-06	4.89e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—IL6—breast cancer	8.29e-06	4.68e-05	CbGpPWpGaD
Apraclonidine—ADRA1A—Signaling Pathways—AKT1—breast cancer	8.23e-06	4.65e-05	CbGpPWpGaD
Apraclonidine—ADRA2A—Signaling Pathways—AKT1—breast cancer	7.65e-06	4.32e-05	CbGpPWpGaD
